Related Experiment Video

Updated: Jun 2, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[Use of mTOR-inhibitors in solid tumors]

Christoph Seidel1, Viktor Grünwald

  • 1Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzell-transplantation, Carl-Neuberg-Strasse 1, 30625 Hannover, Seidel.Christoph@mh-hannover.de

Medizinische Monatsschrift Fur Pharmazeuten
|May 3, 2011
PubMed

Insights

Mammalian target of rapamycin (mTOR)-inhibitors offer chronic treatment options for metastatic renal cell carcinoma and other cancers. While associated with common side effects like stomatitis, severe adverse events are rare, supporting their use in combination therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Translational Medicine

Background:

  • Mammalian target of rapamycin (mTOR)-inhibitors are targeted therapies used clinically, particularly for metastatic renal cell carcinoma.
  • Unlike traditional chemotherapy, targeted agents necessitate chronic treatment, altering the approach to managing adverse events (AEs).

Purpose of the Study:

  • To review the adverse event profile of mTOR-inhibitors.
  • To discuss the potential of mTOR-inhibitors in combination therapies.
  • To highlight emerging applications of mTOR-inhibitors in various tumor types.

Main Methods:

  • Review of clinical data and literature on mTOR-inhibitor therapy.
  • Analysis of common and severe adverse events associated with mTOR-inhibitors.
  • Evaluation of ongoing clinical trials and therapeutic applications.

Main Results:

  • mTOR-inhibitors are associated with common class effects including stomatitis, infection, pneumonitis, hyperlipidemia, and hyperglycemia.
  • Severe adverse events are infrequent, supporting the chronic use of these agents.
  • Promising results are emerging for mTOR-inhibitors in neuroendocrine tumors, mantle cell lymphoma, and sarcomas.

Conclusions:

  • mTOR-inhibitors demonstrate a favorable tolerability profile for chronic use, with manageable class effects.
  • Their potential for combination therapies is significant, though hepatic metabolism requires careful consideration for drug interactions.
  • mTOR-inhibitors, including everolimus and temsirolimus, are integral to current treatment paradigms for metastatic renal cell carcinoma and show promise in other malignancies.

More Related Videos

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...